“The mission of UCB Immunology is to deliver value beyond expectations to our patients. We know that many people living with immunological diseases experience suboptimal response on existing therapies. This unmet need drives UCB’s patient-centric approach towards scientific research and improving the patient experience,” said Emmanuel Caeymaex, Head of Immunology and Executive Vice President at UCB, Immunology Patient Value Unit, UCB. “Cimzia® data at the Annual European Congress of Rheumatology (EULAR 2016) help to build increased understanding around the product’s long-term safety and efficacy profile, while our pipeline data demonstrate momentum in bringing innovative new products to patients.”
Data highlights will include four-year efficacy and safety data from both the RAPID-axSpA trial for the treatment of patients with axSpA, including ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA), and the RAPID-PsA trial for the treatment of patients with PsA. Period 2 data from the C-EARLY™ Phase 3 study will be presented, comparing different treatment strategies by continuing CIMZIA® at the standard dose or reducing the dose frequency versus withdrawal, in disease-modifying antirheumatic drug (DMARD)-naïve early RA patients who achieved sustained low disease activity after one year of treatment with certolizumab pegol combined with optimized methotrexate.
Data being presented from UCB’s pipeline include Phase 3 results from the STRUCTURE study of romosozumab for osteoporosis in post-menopausal women, Phase 1b results in PsA for bimekizumab (UCB4940), an investigational monoclonal antibody specifically designed to potently and selectively inhibit the biological function of both IL-17A and IL-17F cytokines, and Phase 1 results for dapirolizumab pegol (CDP7657), an anti-CD40L pegylated Fab fragment being evaluated for SLE.